Joseph P. Hagan - 17 May 2021 Form 4 Insider Report for Regulus Therapeutics Inc. (RGLS)

Role: President and CEO, Director
Signature: Christopher Aker, Attorney in Fact
Issuer symbol: RGLS
Transactions as of: 17 May 2021
Net transactions value: -$3,726
Form type: 4
Filing time: 17 May 2021, 19:13:47 UTC
Next filing: 14 Jun 2021
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	RGLS	Common Stock	Sale	$3,726	-4,186	-1.3%	$0.8900	316,292	17 May 2021	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The sales reported on this Form 4 represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs) received by the Reporting Person on 11/12/2018. These sales are made pursuant to an existing 10b5-1 plan under which the Reporting Person has irrevocably elected to satisfy the tax obligations through this sale and do not represent discretionary trades by the Reporting Person.

Content

The sales reported on this Form 4 represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs) received by the Reporting Person on 11/12/2018. These sales are made pursuant to an existing 10b5-1 plan under which the Reporting Person has irrevocably elected to satisfy the tax obligations through this sale and do not represent discretionary trades by the Reporting Person.